Axitinib 5 mg is an oral medication used primarily in the treatment of advanced renal cell carcinoma, which is a type of kidney cancer, especially in cases where one or more previous cancer therapies have not been effective. It belongs to a class of drugs known as tyrosine kinase inhibitors and works by blocking certain proteins that promote the growth of abnormal blood vessels and cancer cells, effectively slowing or stopping cancer progression. Axitinib is usually prescribed as part of a specialized cancer treatment plan and may be used alone or in combination with immunotherapy agents such as avelumab or pembrolizumab.